Holen Sie sich die Stockscreener-App
75.84
2.77%
-2.16
Handel nachbörslich:
74.76
-1.08
-1.42%
Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Spruce Biosciences Appoints Keli Walbert as Director - The Globe and Mail
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directo - PharmiWeb.com
Spruce Biosciences appoints Keli Walbert to board of directors - marketscreener.com
Spruce Biosciences Appoints Keli Walbert To Board Of Directors - TradingView — Track All Markets
Spruce Biosciences (NASDAQ: SPRB) names rare-disease veteran Keli Walbert to board - Stock Titan
Wall Street Zen Upgrades Spruce Biosciences (NASDAQ:SPRB) to Hold - MarketBeat
Spruce Biosciences (SPRB) Price Target Increased by 55.76% to 213.69 - Nasdaq
Spruce Biosciences (NASDAQ:SPRB) Raised to Strong-Buy at Leerink Partnrs - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Outperform" at Leerink Partners - MarketBeat
Leerink Partners Upgrades Spruce Biosciences (SPRB) - Nasdaq
Spruce Biosciences Shares Rise After Upgrade From Leerink - marketscreener.com
SPRB: Leerink Partners Upgrades to Outperform with $160 Target | - GuruFocus
Leerink Partners upgrades Spruce Biosciences stock to Outperform By Investing.com - Investing.com Canada
Leerink Partners upgrades Spruce Biosciences stock to Outperform - Investing.com
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close - Nasdaq
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Spruce Biosciences (SPRB) Price Target Increased by 2,045.14% to 137.19 - Nasdaq
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Sell" at Wall Street Zen - MarketBeat
Is Spruce Biosciences Stock Built to Withstand More Downside? - Trefis
Citizens Jmp Forecasts Strong Price Appreciation for Spruce Biosciences (NASDAQ:SPRB) Stock - MarketBeat
Citizens raises Spruce Biosciences stock price target to $259 on MPS IIIB therapy - Investing.com Australia
Citizens raises Spruce Biosciences stock price target to $259 on MPS IIIB therapy By Investing.com - Investing.com South Africa
Citizens Maintains Spruce Biosciences (SPRB) Market Outperform Recommendation - Nasdaq
SPRB: Citizens Raises Price Target for Spruce Biosciences | SPRB Stock News - GuruFocus
Spruce Biosciences Reports Q3 2025 Financial Results - TipRanks
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - BioSpace
SPRB Announces Key Financing Milestones and Regulatory Achieveme - GuruFocus
Spruce Biosciences Q3 net loss narrows - MarketScreener
Spruce Biosciences Inc expected to post a loss of $13.93 a shareEarnings Preview - TradingView
Spruce Biosciences (SPRB) Expected to Announce Earnings on Monday - MarketBeat
One new option listing and two option delistings on September 5th - MSN
Small Cap Stocks To Follow TodayOctober 6th - MarketBeat
Biotech And Tech Stocks Rally On Breakthrough News And Partnerships - Finimize
Spruce Biosciences (SPRB) Price Target Decreased by 37.30% to 6.40 - MSN
[S-3] SPRUCE BIOSCIENCES, INC. Shelf Registration Statement | SPRB SEC FilingForm S-3 - Stock Titan
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Rating of "Hold" by Brokerages - MarketBeat
Spruce Biosciences (NASDAQ:SPRB) Upgraded to "Outperform" at Citizens Jmp - MarketBeat
Spruce Biosciences Stock Rallied 1184%Have You Assessed the Risk - Trefis
JMP Securities Upgrades Spruce Biosciences (SPRB) - Nasdaq
Cash per share of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView
SPRB: JMP Securities Upgrades Spruce Biosciences to Market Outpe - GuruFocus
Spruce Biosciences Raised to Market Outperform From Market Perform by JMP Securities - 富途牛牛
Spruce Biosciences stock upgraded by Citizens on promising MPS IIIB therapy - Investing.com Nigeria
Spruce Biosciences Stock Dropped 16%Have You Assessed the Risk - Trefis
Spruce Biosciences (NASDAQ:SPRB) Stock Rating Lowered by Zacks Research - MarketBeat
What is Leerink Partnrs' Forecast for SPRB FY2025 Earnings? - MarketBeat
Levi & Korsinsky Reminds Spruce Biosciences Investors of the Ongoing Investigation into Potential Violations of Securities LawsSPRB - ACCESS Newswire
Spruce Biosciences Announces $50 Million Private Placement Financing - Global Legal Chronicle
Spruce Biosciences CFO vests 2,053 RSUs; owns 6,066 shares - Stock Titan
SPRB insider filing: CEO nets 3,245 shares after RSU vest - Stock Titan
The science behind the therapy that catapulted a biopharma’s stock 1,400% and counting - Healthcare Brew
Leerink Partners Maintains Spruce Biosciences (SPRB) Market Perform Recommendation - Nasdaq
0.18%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):